Analysts’ Recent Ratings Updates for SiBone (SIBN)

SiBone (NASDAQ: SIBN) recently received a number of ratings updates from brokerages and research firms:

• 8/5/2026 – SiBone was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 8/4/2026 – SiBone had its price target raised by UBS Group AG from $24.00 to $25.00. They now have a “buy” rating on the stock.
• 8/4/2026 – SiBone had its price target raised by TD Cowen from $18.00 to $20.00. They now have a “buy” rating on the stock.
• 8/4/2026 – SiBone had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $23.00 price target on the stock, up from $21.00.
• 7/28/2026 – SiBone is now covered by UBS Group AG. They set a “buy” rating and a $24.00 price target on the stock.
• 7/28/2026 – SiBone is now covered by UBS Group AG. They set a “buy” rating and a $24.00 price target on the stock.
• 7/21/2026 – SiBone was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/16/2026 – SiBone had its price target raised by Truist Financial Corporation from $18.00 to $21.00. They now have a “buy” rating on the stock.
• 7/2/2026 – SiBone had its “sell (e+)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling

In other news, Director Timothy E. Davis, Jr. sold 3,500 shares of SiBone stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $14.14, for a total value of $49,490.00. Following the completion of the transaction, the director owned 65,722 shares in the company, valued at approximately $929,309.08. The trade was a 5.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jeffrey W. Dunn sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $18.46, for a total value of $369,200.00. Following the completion of the transaction, the director directly owned 16,057 shares in the company, valued at $296,412.22. The trade was a 55.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 37,306 shares of company stock valued at $635,901. 4.00% of the stock is currently owned by company insiders.

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.